Viking Therapeutics Inc. is progressing its oral drug VK2735 into Phase III trials for obesity treatment following promising results from earlier phases. This move comes amid a tumultuous period for the company, highlighted by a 42% drop in stock value due to mixed trial outcomes and recent Q1 earnings misses. Nevertheless, Viking boasts a market capitalization of $3.68 billion and a robust cash runway, positioning it well for future developments in the obesity drug market.
“Viking Therapeutics · plans to advance · oral VK2735 into phase III development for obesity · true”
“Viking Therapeutics · is developing · VK2735 as oral and subcutaneous formulations for obesity · true”
“Viking Therapeutics · is developing · VK2735 · for the treatment of obesity”
“Viking Therapeutics Inc. · has market capitalization of · $3.68B”
“Viking Therapeutics Inc. · closed at · $30.27”
“Viking Therapeutics Inc. · had a post market change of · $0.20 · (0.66%)”
“Viking Therapeutics Inc. · had a daily change of · $1.44 · (4.54%)”
“Viking’s research and development activities · leverage · expertise in metabolism · to develop innovative therapeutics designed to improve patients’ lives”
“Viking’s clinical programs · include · VK2735 · a novel dual agonist of the GLP-1 and GIP receptors”
“The company · is evaluating · VK2735 · in a Phase 3 obesity program”
“The company · is evaluating · an oral formulation of VK2735 · in obesity”
“Viking · is developing · VK2809 · a novel, orally available, small molecule selective thyroid hormone receptor beta agonist”
.jpg&width=160)